Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Each ingredient below shows whether it has known drug interactions
A slower escalation may be needed if side effects are troublesome Eat smaller, more frequent meals and avoid high-fat foods Stay well hydrated, particularly if experiencing vomiting or diarrhoea, to reduce the risk of dehydration and acute kidney injury Take the injection at a consistent time that minimises symptom impact Treatment continuation criteria , aligned with NICE guidance (TA664), recommend: Assessing weight loss after 12 weeks at the 3.0 mg maintenance dose Continuing treatment only if at least 5% of initial body weight has been lost Discontinuing Saxenda if adequate weight loss is not achieved or maintained Treatment typically limited to up to 2 years within specialist weight management services Patient safety considerations include proper injection technique, rotating injection sites to prevent lipodystrophy, and appropriate medication storage (refrigerated before first use, then at room temperature for up to one month)
(Front Pharmacol, 2018) conducted a 6-month safety study with injectable BPC-157, finding no significant changes in liver function, kidney parameters, or hematologic markers
10.2337/diabetes.53.5.1326 44
Retrieved 14 December 2017
launched a biosimilar of the popular anti-diabetic drug Liraglutide in India, marketing it as Lirafit after obtaining approval from the Drug Controller General of India (DCGI)
US$ 25.44
US$ 26.59
US$ 24.95
US$ 22.87
US$ 28.98
